Mankind Pharma stock surges 9% after strong Q2 results; Kotak sees big upside, other brokerages cautious

What happened

Mankind Pharma shares surged over 9 percent on Tuesday, climbing 9.3 percent to Rs 2,527 in afternoon trade, after strong Q2 FY27 earnings. The stock had gained 4.5 percent in the previous session following the earnings announcement.

Confirmed

Global impact / market context

The jump shows investors reward strong earnings, but broker views differ. Kotak sees about 31 percent upside to Rs 3,035, while Bernstein and Macquarie flag valuation and weak consumer healthcare recovery, so future gains depend on delivered growth.

Analyst inference

The move came as the Nifty Pharma index rose 1.7 percent, meaning sector-wide buying boosted the stock. Mankind's market value near Rs 1.04 lakh crore and its 2026 outperformance versus the Nifty 50 show investors already expect sustained earnings growth.

Analyst inference

What to watch

1. Kotak expects Mankind to beat the Indian pharmaceutical market by 1.1 to 1.2 times over the next two quarters, so watch whether reported sales growth meets that pace. Confirmed
2. Watch whether Bernstein and Macquarie change their cautious views on valuation and the uneven consumer healthcare recovery, since upgrades could draw more buyers and downgrades could pressure the stock. Proposed
3. Watch the Nifty Pharma index: if sector strength fades, Mankind's rally may lose support, because part of the gain came from broader pharmaceutical buying rather than company results alone. Analyst inference

Evidence

• Original source link unavailable